Naixin Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1434824/publications.pdf

Version: 2024-02-01

		430874	434195
58	1,116	18	31
papers	citations	h-index	g-index
C 1	C 1	C 1	1576
64	64	64	1576
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Medicine, 2020, 18, 87.	5.5	189
2	Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nature Biomedical Engineering, 2021, 5, 586-599.	22.5	74
3	Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus. Oncotarget, 2017, 8, 77400-77406.	1.8	72
4	⁶⁸ Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer. Journal of Nuclear Medicine, 2015, 56, 1823-1827.	5.0	68
5	Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution. Oncology Reports, 2017, 37, 1347-1358.	2.6	63
6	Postoperative pain experiences in Chinese adult patients after thoracotomy and videoâ€assisted thoracic surgery. Journal of Clinical Nursing, 2017, 26, 2744-2754.	3.0	47
7	Expression and prognostic analyses of <i>ITGA11</i> , <i>ITGB4</i> and <i>ITGB8</i> in human non-small cell lung cancer. Peerl, 2019, 7, e8299.	2.0	42
8	Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 730320.	4.8	39
9	Integrin Imaging with ^{99m} Tc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from Non–Small Cell Lung Cancer. Radiology, 2016, 281, 958-966.	7.3	34
10	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Translational Lung Cancer Research, 2019, 8, 1163-1173.	2.8	34
11	Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. Targeted Oncology, 2019, 14, 159-168.	3.6	33
12	Downregulation of a novel long noncoding RNA TRPM2-AS promotes apoptosis in non–small cell lung cancer. Tumor Biology, 2017, 39, 101042831769119.	1.8	32
13	Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. Oncotarget, 2017, 8, 23130-23141.	1.8	29
14	Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. Gene, 2018, 675, 278-284.	2.2	27
15	Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN. Acta Biochimica Et Biophysica Sinica, 2015, 47, 530-538.	2.0	25
16	Preoperative Prediction of Lymph Node Metastasis in Patients With Early-T-Stage Non-small Cell Lung Cancer by Machine Learning Algorithms. Frontiers in Oncology, 2020, 10, 743.	2.8	25
17	Temozolomide encapsulated and folic acid decorated chitosan nanoparticles for lung tumor targeting: improving therapeutic efficacy both <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 111318-111332.	1.8	23
18	Visfatin mediates doxorubicin resistance in human non–smallâ€cell lung cancer <i>via</i> Aktâ€mediated upâ€regulation of <scp>ABCC</scp> 1. Cell Proliferation, 2017, 50, .	5.3	21

#	Article	IF	Citations
19	Estrogenâ€related receptor alpha triggers the proliferation and migration of human nonâ€small cell lung cancer via interleukinâ€6. Cell Biochemistry and Function, 2018, 36, 255-262.	2.9	18
20	Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles. Journal of Thoracic Disease, 2020, 12, 4262-4273.	1.4	17
21	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Science, 2022, 113, 648-659.	3.9	16
22	Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. Journal of Translational Medicine, 2020, 18, 380.	4.4	14
23	[ARTICLE WITHDRAWN] MicroRNA-539 Inhibits the Epithelialâ€Mesenchymal Transition of Esophageal Cancer Cells by Twist-Related Protein 1-Mediated Modulation of Melanoma-Associated Antigen A4. Oncology Research, 2018, 26, 529-536.	1.5	13
24	KLF8 overexpression promotes the growth of human lung cancer cells by promoting the expression of JMJD2A. Cancer Cell International, 2019, 19, 258.	4.1	13
25	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. Journal of Thoracic Disease, 2020, 12, 2771-2780.	1.4	13
26	FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop. Life Sciences, 2021, 287, 120012.	4.3	13
27	Peripheral primitive neuroectodermal tumors arising in the pancreas: the first case report in Asia and a review of the 14 total reported cases in the world. Hepatobiliary Surgery and Nutrition, 2013, 2, 51-60.	1.5	11
28	Genomeâ€'wide DNA methylation profile of thymomas and potential epigenetic regulation of thymoma subtypes. Oncology Reports, 2019, 41, 2762-2774.	2.6	10
29	Predicting occult lymph node metastasis byÂnomogram in patients with lung adenocarcinoma â‰ 2 Âcm. Future Oncology, 2021, 17, 2005-2013.	2.4	10
30	First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. Journal of Thoracic Disease, 2020, 12, 3764-3773.	1.4	8
31	Metastatic Patterns of Mediastinal Lymph Nodes in Small-Size Non-small Cell Lung Cancer (T1b). Frontiers in Surgery, 2020, 7, 580203.	1.4	7
32	Clinicopathological models for predicting lymph node metastasis in patients with early-stage lung adenocarcinoma: the application of machine learning algorithms. Journal of Thoracic Disease, 2021, 13, 4033-4042.	1.4	7
33	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients. Translational Lung Cancer Research, 2021, 10, 3888-3901.	2.8	7
34	Identifying an Eight-Gene Signature to Optimize Overall Survival Prediction of Esophageal Adenocarcinoma Using Bioinformatics Analysis of ceRNA Network. OncoTargets and Therapy, 2020, Volume 13, 13041-13054.	2.0	7
35	An Externally-Validated Dynamic Nomogram Based on Clinicopathological Characteristics for Evaluating the Risk of Lymph Node Metastasis in Small-Size Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1322.	2.8	6
36	Transcriptomic and Mutational Analysis Discovering Distinct Molecular Characteristics Among Chinese Thymic Epithelial Tumor Patients. Frontiers in Oncology, 2021, 11, 647512.	2.8	6

#	Article	lF	Citations
37	Clinical implications of EGFRâ€associated MAPK/ERK pathway in multiple primary lung cancer. Clinical and Translational Medicine, 2022, 12, e847.	4.0	6
38	Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Frontiers in Oncology, 2021, 11, 537735.	2.8	5
39	Pathological complete response to neoadjuvant ceritinib of a crizotinibâ€resistant, stage <scp>IllB</scp> nonâ€small cell lung cancer with <scp>ALK</scp> rearrangement: A case report. Thoracic Cancer, 2021, 12, 2130-2133.	1.9	5
40	Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer. Nanomaterials, 2022, 12, 809.	4.1	5
41	Prognostic study for survival outcome following the treatment of second primary lung cancer in patients with previously resected nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 2840-2851.	1.9	4
42	DNA methylation patterns at and beyond the histological margin of early-stage invasive lung adenocarcinoma radiologically manifested as pure ground-glass opacity. Clinical Epigenetics, 2021, 13, 153.	4.1	4
43	Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. Frontiers in Pharmacology, 2021, 12, 809467.	3.5	3
44	Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report. Annals of Palliative Medicine, 2020, 9, 4339-4345.	1.2	2
45	Clinical manifestations and long-term prognosis of Good syndrome: Results from a single-center cohort study from China. Modern Rheumatology, 2021, 31, 1019-1024.	1.8	2
46	HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1383-1396.	2.8	2
47	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. Translational Lung Cancer Research, 2021, 11, 0-0.	2.8	2
48	Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study. BMC Pulmonary Medicine, 2020, 20, 80.	2.0	1
49	The predictive values of loss-of-function variants in histone methyltransferases for response to immune checkpoint inhibitors in solid tumors Journal of Clinical Oncology, 2021, 39, 2586-2586.	1.6	1
50	Surgical treatment of tracheal extramedullary plasmocytoma and pertinent literature review. Chinese-German Journal of Clinical Oncology, 2007, 6, 193-195.	0.1	0
51	Comprehensive T-cell receptor repertoire of Chinese lung cancer patients related with age Journal of Clinical Oncology, 2021, 39, e21076-e21076.	1.6	0
52	Abstract 1639: Correlation of KMT2C/Dloss-of-function mutations with PD-L1 expression and response to immune checkpoint inhibitors in solid tumors. , 2021, , .		0
53	Abstract 2252: Genome profiling of thymic carcinoma identifies putative driver mutations in the NF- $\hat{\mathbb{I}}^2B$ signaling pathway. , 2021, , .		0
54	Oncogenic mutation within the $\hat{l}^23-\hat{l}\pm C$ loop of EGFR/ERBB2/BRAF/MAP2K1 Journal of Clinical Oncology, 2018, 36, e24299-e24299.	1.6	0

#	Article	IF	CITATIONS
55	BRAF V600 and non-V600 mutations across distinct tumor types Journal of Clinical Oncology, 2018, 36, e24297-e24297.	1.6	O
56	Genetic profiling and TCR repertoire feature of synchronous multiple primary lung carcinomas Journal of Clinical Oncology, 2020, 38, e21031-e21031.	1.6	0
57	Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine, 2020, 8, 1415.	1.7	0
58	An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection Journal of Clinical Oncology, 2022, 40, 3037-3037.	1.6	0